secwatch / observer
8-K filed December 20, 2023, 6:59 PM ET ticker CELZ CIK 0001187953
other material confidence high sentiment neutral materiality 0.15

Shareholders elect all five director nominees and approve say-on-pay at annual meeting

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Election of five director nominees to the Board at the 2023-12-20 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-12-20
Exact text from the filing
Timothy Warbington 237,163 24,057 Donald Dickerson 237,192 24,028 Michael H. Finger 234,462 26,758 Susan Snow 237,729 23,491 Bruce S. Urdang, Esq. 235,547 25,673
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Approval of the compensation of the Company's named executive officers at the 2023-12-20 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2023-12-20
Exact text from the filing
For Against Abstain Broker Non-Votes 169,498 90,645 1,077 515,762
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. shareholders approved Ratification of the appointment of Haynie & Company to serve as the Company's independent registered public accountants at the 2023-12-20 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-12-20
Exact text from the filing
For Against Abstain Broker Non-Votes 751,848 23,485 1,649 N/A
View on SEC.gov

1668 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR
accession 0001477932-23-009261
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.